Cayman RIPGBM

RIPGBM is a prodrug form of the pro-apoptotic compound cRIPGBM. It is converted to cRIPGBM in GBM-1 glioblastoma multiforme (GBM) cancer stem cells (CSCs) but not primary human lung fibroblasts (HLFs). RIPGBM induces apoptosis in GBM CSCs (EC₅₀ = ≤500 nM) and selectively reduces survival of GBM-1 cells (EC₅₀ = 0.22 μM) over human neural stem cells, primary human astrocytes, and primary HLFs (EC₅₀s = 1.7, 2.9, and 3.5 μM, respectively). It reduces tumor growth in a GBM mouse xenograft model using patient-derived GBM-39 cells engineered to express IR fluorescent protein 720 (IRFP720) when administered at a dose of 50 mg/kg twice per day.

WARNING This product is not for human or veterinary use.